Norgine Healthcare

Norgine is a leading European specialist pharmaceutical company with a history spanning over 115 years. The company focuses on developing, manufacturing, and commercializing innovative products across several core therapeutic areas, including gastroenterology, hepatology, oncology, and rare diseases. Norgine operates a fully integrated business model with a strong European footprint, maintaining its own development and manufacturing facilities in the UK and France. Its commercial portfolio features well-established brands such as MOVICOL, PLENVU, and XIFAXAN 550. In 2022, Goldman Sachs Asset Management acquired a majority stake in the company to accelerate its growth strategy through organic development and strategic acquisitions.